{"id":"ag-d-cik","safety":{"commonSideEffects":[{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that is overexpressed on the surface of cancer cells and is involved in immune evasion. By targeting CD47, Ag-D-CIK aims to enhance the body's immune response against cancer cells.","oneSentence":"Ag-D-CIK is a monoclonal antibody that targets CD47.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:18.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT02215837","phase":"PHASE2","title":"Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-08","conditions":"Gastric Cancer, Neoplasms, Gastrointestinal Neoplasms","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ag-D-CIK","genericName":"Ag-D-CIK","companyName":"Shenzhen Hornetcorn Bio-technology Company, LTD","companyId":"shenzhen-hornetcorn-bio-technology-company-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ag-D-CIK is a treatment that combines autologous tumor lysate-pulsed dendritic cells and cytokine-induced killer cells, and it has been studied in clinical trials for various conditions including gastric cancer, neoplasms, and gastrointestinal diseases. Ag-D-CIK is used in conjunction with chemotherapy in a randomized, controlled, multicenter study for the treatment of gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}